医学
恩扎鲁胺
中止
前列腺癌
肿瘤科
内科学
危险系数
临床终点
多西紫杉醇
临床试验
比例危险模型
毒性
阿比曲酮
前列腺特异性抗原
醋酸阿比特龙酯
雄激素剥夺疗法
临床实习
封锁
抗雄激素
放射治疗
随机对照试验
退伍军人事务部
联合疗法
临床研究阶段
不利影响
中期分析
代理终结点
生存分析
低风险
癌症
置信区间
作者
Takashi Ueda,Keita Hayakawa,Yuki Ota,Junki Murashita,Hikaru Takahashi,Yumiko Saito,Masatsugu Miyashita,Takumi Shiraishi,Atsuko Fujihara,Masayoshi Okumi,Yuta Asakawa,Yuki Harada,Takeshi Yamada,Osamu Ukimura
摘要
BACKGROUND: Though randomized trials established androgen-receptor signaling inhibitor (ARSI) doublets and darolutamide-docetaxel triplet therapy (TRI) for metastatic hormone-sensitive prostate cancer, combined androgen blockade (CAB) remains widely used in Japan and these strategies have not been compared directly. METHODS: We retrospectively analysed 643 men with M1 disease who began androgen-deprivation therapy during 2020-2026 at 23 Japanese institutions: CAB (113), abiraterone (139), enzalutamide (166), apalutamide (APA; 116), or TRI (109). The primary endpoint was castration-resistance-free survival (PFS1). Groups were compared by Kaplan-Meier analysis and multivariable Cox regression, with inverse-probability-of-treatment weighting, restriction to 2023-2026, and propensity-score matching as sensitivity analyses. RESULTS: Median PFS1 was 16.1, 37.5, 54.9, and 52.9 months, respectively, and was not reached with TRI (P < .001). Adjusted hazard ratios versus CAB were 0.50 (95% CI 0.34-0.72), 0.43 (0.28-0.66), 0.42 (0.26-0.66), and 0.20 (0.10-0.41); triplet versus pooled ARSI doublets was 0.45 (0.24-0.85), exploratory and resting on 12 events. The ordering was preserved in all sensitivity analyses. Prostate-specific antigen 90 (PSA90) rates were similar (94.7%-95.8%), whereas a PSA nadir ≤0.2 ng/ml rose from 43.4% (CAB) to 68.9% (triplet; P < .001). Overall survival was immature (141 deaths). Discontinuation for toxicity was most frequent with APA (19.8%); 54.1% of triplet-treated patients completed six docetaxel cycles. CONCLUSIONS: Intensified first-line treatment was associated with a substantially lower hazard of castration resistance than CAB. The further reduction with TRI rests on few events and is exploratory. Discontinuation for toxicity was most frequent with APA, but ascertainment differed between the registry streams, so safety comparisons are hypothesis-generating.
科研通智能强力驱动
Strongly Powered by AbleSci AI